ナノキャリア株式会社 - xml.irpocket.com

1 4571 NIKKEI 2017 7 22 Leading Edge Nanotechnology 1996 / 2000 2008 2017 ( / 226 39 144 39 1-4-10 iCONM 2 1996 6 14 2008 3 5 11,085 (2017 3 31 43,179,384 2017 3 31 68 2017 3 31 CEO CFO COO ( 3 / / POC 4 30 100 5 System DesignMedicelle Medicelle NanoCap NanoCap 30 100nm ADCM(Antibody/Drug Conjugated Micelle))))

2 ADCM(Antibody/Drug Conjugated Micelle) NK105 siRNA NC-6004 NC-4016 NC-6300 Active Targeting NC-6201 E7974) 6 EPR Enhanced permeability and retention effect Y. Matsumura, et al., Cancer Research1986, 46, 6387. 7 8 6004 1. 2. 3. 1. 2. 3. Quality Of Life Quality of Life (QOL): / 6004 20406080 Pt (g/mL)Time(hr) NC-6004 NC-6004 01234567 Plasma Level Pt g/g Time NC-6004 10 min1h6h24h48hNC-6004 NC-6004 Hydration Cl- pH 9 6004 10 NC-6004 Hydration Hydration FOLFIRINOX1 46 1 FOLFIRINOX 4 (Oxaliplatin, Leucovorin, Irinotecan, 5-FU)

3 PD 1 [BMS ] CTLA 4 PD L1 [ ] Bavencio [ ] [ ] Imfinzi [ ] [BMS] [ ] 11 NK105 2017 5 11 ph1ph2ph3 NC-6004 / / / NC-4016 NC-6300 NC-6201E7974( ) ActiveNanoFectsiRNA NK105 12NC 6004 / 13NC 6004 NC 6004 400 303 III NC 6004 90 mg/m2 3 1 1000 mg/m23 2 VS.

4 1000 mg/m24 3 OS OEP OEP 14NC 6004 NC 6004 Ib 3 3 II 15 3 13 NC 6004 NC 6004135 mg/m23 1 1,250 mg/m23 2 NC 6004 / NC 6004 I/II NC 6004 5 FU NC 6004 5 FU I OEP OEP 90 mg/m2 15NC 6300 H IND 2016 12 30 I/II ( 10 I/II I II 60 mg/m2 100 mg/m2 170 mg/m2 12 I 162017 Investigator Meeting in Chicago17 2017 6 5 Chicago Marina)

5 Prof. Kazunori KataokaICONM: 18 24 King Kawasaki INnovation Gateway SkyFront / 1 / 100 /1 19 / Active NanoFect Active NanoFect ADCM Antibody/Drug Conjugated Micelle)NanoFect ADC 20 Biologics NASDAQ TPG Biologics Tocagen ADCM 21 2010 e clafutur-W : / 2013 eclafutur : / 2014 2016 / / 2016 EXCIA AL.

6 / 2220172017 Not only But also 23 CLEANING MOISTURE BOOSTER ADVANCEPART 01 PART 02 PART 03 PART 04 DDS 5 ALBION DRESSER 3F)247 1 Depth KIKKAKE @ Depth Depth KIKKAKE @ Depth / 25 03 3241 0553